- Previous Close
36.41 - Open
34.96 - Bid --
- Ask --
- Day's Range
31.79 - 36.46 - 52 Week Range
1.72 - 54.30 - Volume
36,873 - Avg. Volume
51,470 - Market Cap (intraday)
204.008M - Beta (5Y Monthly) 1.19
- PE Ratio (TTM)
-- - EPS (TTM)
-1.98 - Earnings Date May 7, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
53.27
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops MNPR-101-Zr, a clinical stage urokinase plasminogen activator receptor-targeted radiodiagnostic imaging agent; and MNPR-101-RIT, a late preclinical stage radiotherapeutic for advanced cancers. It also develops Camsirubicin, a Phase 1b clinical stage novel analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; and MNPR-202, an analog of Camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. Monopar Therapeutics Inc. is a subsidiary of Tacticgem LLC.
www.monopartx.comRecent News: MNPR
View MorePerformance Overview: MNPR
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MNPR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MNPR
View MoreValuation Measures
Market Cap
222.01M
Enterprise Value
214.74M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
44.88
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-59.67%
Return on Equity (ttm)
-112.04%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-6.47M
Diluted EPS (ttm)
-1.98
Balance Sheet and Cash Flow
Total Cash (mrq)
6.02M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.87M